Abdul Mannan: APTT Mixing Studies Confuse a Lot of People
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared on LinkedIn:
”APTT mixing studies confuse a lot of people.
Let me show you why the incubated step matters.
Factor VIII is thermally labile. At 37°C, it naturally decays over 1-2 hours.
This isn’t pathology—it’s normal biology.
But here’s the trick: this can look exactly like a time-dependent inhibitor if you’re not careful.
The solution? Run parallel tests.
Here’s what you need to know:
- Test both immediate AND incubated samples (at 2 hours)
- Compare patient plasma alone vs 1:1 mix with normal pooled plasma
- Normal thermal decay: slight drift in both NPP and 1:1 mix
- Time-dependent inhibitor: the 1:1 mix prolongs MORE than NPP control
- Golden rule: If Δ(1:1 Mix) > Δ(NPP Control), think inhibitor
The pattern tells the story.
Normal FVIII lability shows similar small shifts in both tubes.
A true inhibitor shows clearly more prolongation in the mix than the control—it’s time AND temperature dependent, not just thermal drift.
Pro tip: Always use properly buffered conditions (Nijmegen-modified) for stability.
Thaw plasma promptly at 37°C and test without delay for routine assays. If you’re uncertain, measure
FVIII:C before and after incubation.
What’s the most challenging APTT mixing study pattern you’ve interpreted recently?”

Stay updated with Hemostasis Today.
-
Oct 5, 2026, 15:31Irma Bagdoniene: Multidisciplinary Management of High-Risk Familial Hypercholesterolaemia and CAD
-
Oct 5, 2026, 15:00Serena Williams and Pulmonary Embolism: From Personal Crisis to Lessons in Venous Thromboembolism
-
Oct 5, 2026, 14:55Marco Moscarelli: 3D Reconstruction Enhances Volumetric Assessment of Post-TAVI Thrombosis
-
Oct 5, 2026, 13:24Abdul Muqtadir Abbasi: Diagnostic Pearls for Evaluating Isolated Thrombocytopenia in Residents
-
Oct 5, 2026, 13:16Katerina Pavenski: Rethinking What ‘Normal’ Means for Iron Deficiency
-
Oct 5, 2026, 13:09Rick Matthews: Balancing Established VTE Partnerships with Innovative Interventional Technologies
-
Oct 5, 2026, 13:01Nawsherwan Mohammad: Recognizing TTP Before the ADAMTS13 Result Arrives
-
Oct 5, 2026, 12:51Bruno Pougault: The Hidden Challenges Behind Anti Xa Testing
-
Oct 5, 2026, 12:41Syed Huzaifa Khan: Rethinking CTRP12 as a Biomarker for In Stent Restenosis